Stryker (SYK) Q2 FY25 earnings call

Stryker delivered robust Q2 FY25 results, driven by strong demand across its diverse portfolio and record Mako installations, leading to double-digit organic sales and adjusted EPS growth. The company raised its full-year outlook, confident in its operational execution and innovation pipeline, despite ongoing supply chain challenges in the Medical segment and integration disruptions from Inari Medical. Management remains active in M&A and sees continued strength in procedural volumes and capital demand.